Home > Neurology > MTIS 2020 > Contents > Concomitant preventive medication has no impact on efficacy of ubrogepant

Concomitant preventive medication has no impact on efficacy of ubrogepant

Presented By
Dr Andrew M. Blumenfeld, Headache Center of Southern California, USA
Conference
MTIS 2020
Trial
Phase 3, ACHIEVE I and II
Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor (CGPR) antagonist, which is FDA-approved for the acute treatment of adult migraine patients with or without aura. Concomitant preventive medication use did not impact the efficacy of ubrogepant and was not associated with additional safety concerns.     Patients with migraine frequently need to take both acute and preventive medications. As ubrogepant is a novel acute treatment, the potential impact of concomitant preventive medication use on the safety and efficacy of ubrogepant is of clinical interest and was investigated in the current study [1]. ACHIEVE trials In the phase 3 ACHIEVE I and ACHIEVE II trials, adults with a history of migraine...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on